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Backgrounds and aims: 
In Indonesia 1.9 million people are chronically infected with hepatitis C virus (HCV), but a national 
strategic plan for elimination has not yet been developed, despite the availability of low-cost 
treatments which could save many lives. We used epidemiological- and cost-modelling to estimate 
targets and resource requirements of a national elimination program and explore the potential 
impact and cost-effectiveness. 
Methods: 
To model the HCV epidemic, we used a dynamic model, parameterised with Indonesia-specific data, 
accounting for disease progression, injecting drug use, and demographics. Future scale-up scenarios 
were designed for 2018-2050 to capture possible policy choices. Costs of an initial five-year national 
strategy and of long-term elimination were estimated for the most feasible scenario, as agreed with 
government and local partners. Cost savings from reduced drug and diagnostics prices were also 
estimated. The cost-effectiveness of baseline predictions and those with drug price reductions were 
compared to the no-treatment scenario. 
Results: 
Elimination by 2045, considered the most feasible path to scale-up, would prevent 739,000 new 
infections and avert 158,000 HCV-related deaths. The costs would be $5.6 billion (USD) using 
baseline prices but could fall to $2.7 billion if price reductions for HCV drugs and diagnostics are 
secured. With these price reductions, the incremental cost-effectiveness ratio for a 2045 elimination 
program would be cost-effective at $300 (USD) per year of life saved versus the no-treatment 
scenario. 
Conclusions: 
This study has underpinned advocacy efforts to secure Indonesian government commitment to HCV 
elimination, and provides further inputs for HCV strategic planning efforts.  
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Lay Summary:  
• Eliminating hepatitis C virus (HCV) in Indonesia by 2045 would prevent 739,000 new 
infections and avert 158,000 HCV-related deaths. 
• With conservative price reductions, the costs of elimination by 2045 are estimated to be 
around $2.7 billion (USD). 
• This would give an incremental cost-effectiveness ratio of $300 (USD) per year of life saved 






Globally, 70 million people are chronically infected with Hepatitis C Virus (HCV), a bloodborne virus 
affecting the liver(1). HCV causes over 400,000 deaths annually from liver complications, including 
hepatocellular carcinoma (HCC) and cirrhosis(1). 
Following the breakthrough of direct acting antivirals (DAAs), which are highly effective cures for 
HCV(2), the World Health Organization (WHO) set global goals for the elimination of HCV(3). These 
ambitious goals call for countries to reduce incident HCV infections by 80% and hepatitis-related 
mortality by 65% by 2030(3, 4). Although there is a growing interest amongst governments to 
control and eliminate HCV, most countries have yet to launch national HCV programs(5). 
In Indonesia, the prevalence of HCV antibodies (anti-HCV) among the general population is 
estimated at 1.0%(6), while the prevalence among people who inject drugs (PWID) is estimated to be 
as high as 90%(7). As the fourth most populous country, Indonesia has one of the largest HCV 
epidemics in the world(8), with an estimated 2.5 million HCV infected people(6). Despite this great 
burden, in 2017 fewer than 1,000 individuals were treated with DAAs(9, 10). Indonesia’s social 
health insurance scheme continues to only cover pegylated interferon, the pre-DAA standard 
therapy with vastly lower sustained virologic response (SVR) rates and toxic side effects(2). DAAs are 
only available at private health facilities and a limited number of public health facilities(5, 10). 
One reason for this delayed scale-up of DAA treatment is a paucity of data and strategic information 
to understand the local burden and potential benefits, and inform strategic planning efforts of policy 
makers(11). As of 2017, a national HCV seroprevalence study had not been conducted nor had a 
national hepatitis strategy based on DAAs been developed. Nonetheless, key building blocks to 
support HCV program scale-up started coming together by 2017. Persaudaraan Korban Napza 
Indonesia (PKNI), the leading advocacy organization for PWID in Indonesia, expanded its efforts on 
awareness campaigns and training for healthcare workers. Treatment guidelines were updated to 
include DAAs for the first time; and the Clinton Health Access Initiative (CHAI) launched the program 
Quick Start, aiming to put 6,000 patients on treatment in the greater Jakarta area over three years to 
demonstrate the feasibility of rolling out a treatment program(12).  
Recognizing that despite these initial steps for developing a national program, Indonesia was still 
missing a long-term strategic plan to guide elimination efforts, our team of advocates and 
technicians used epidemiological and cost modelling to: (a) estimate the projected impact and cost-
effectiveness of an elimination program to support advocacy efforts for securing national 
commitment and (b) produce a framework to help establish a timeline, targets, and resource 








There is a growing body of viral hepatitis investment cases(13-15) that have been used to push for 
accelerated government and donor action to support and finance national strategies(16). In 
Indonesia, there was interest among stakeholders (ministry of health [MoH], local advocates, 
international technical partners) to develop such a tool to secure additional investment.  
In the absence of a national strategy, we needed to first develop a high-level intervention framework 
to guide modelling analyses, based on previous national plans for hepatitis elimination in South 
Africa, Morocco, and Senegal(13, 17). Table 1 shows the priority areas and main activities of this 
framework. The full framework is in the supplement. We then applied several elements of an 
investment case, including disease modelling, cost estimation, and cost-effectiveness analysis to 
generate evidence to guide advocacy and planning efforts. 
Scenario design 
To understand the range of possible policy responses, we modelled treatment scale-up scenarios of 
varying elimination timeframes and scale-up intensity. The WHO definition for elimination is an 80% 
reduction in HCV incidence and a 65% reduction in HCV-related mortality from 2015 levels.  
A “no treatment” scenario was designed to represent the counterfactual of treatment scale-up 
where no patients would receive treatment from 2018-2050. We then explored four elimination 
scenarios: elimination by 2036, 2040, 2042, and by 2045. Elimination by 2030, as per the WHO’s 
overall target, was found to be impossible even if all infected people were treated in 2019, due to 
the existing burden of irreversible liver cirrhosis leading to HCV-related deaths. Elimination by 2036 
represented the most aggressive elimination scenario, with other scenarios designed to represent 
increasingly more gradual paths to scale-up. 
Epidemiological model 
To simulate the HCV epidemic among the general population and PWID in Indonesia, a dynamic, 
deterministic HCV transmission model was used, incorporating population growth, age 
demographics, and HCV progression. The age groups included were: 0-14, 15-34, and ≥35-year olds. 
Supplementary figure 1 shows how the population was stratified into individuals who had never 
injected drugs, people who inject drugs currently (henceforth referred to as PWID), and ex-injectors. 
Initiation of injecting is assumed to occur only among 15-34-year olds. PWID cease injecting at a 
fixed rate to become ex-injectors. 
Individuals enter the model susceptible to infection (except those infected through mother-to-child 
transmission). HCV transmission occurs at a specific modelled rate among all individuals in the 
general population due to medical/community risk factors and occurs at an additional modelled rate 
due to injecting drug use (IDU) among current PWID. Infected individuals either spontaneously clear 
their infection, and return to the susceptible class, or then develop chronic infection. Chronically 
infected individuals then gradually progress through different HCV-related disease stages (chronic 
infection, compensated cirrhosis (CC), and decompensated cirrhosis (DC); supplementary figure 2). 
Individuals in the DC stages have increased HCV-related mortality. Individuals can also die at age-
specific death rates or from drug-related mortality among PWID. After successful DAA treatment 




susceptible, whilst those not achieving SVR transition back to chronic infection. Those who achieve 
SVR can become re-infected. 
The model is described further in the supplement. 
Model parameterization  
Information on population sizes, age distributions, and mortality rates were taken from United 
Nations datasets(18). Anti-HCV prevalence data in the Indonesian general population, 1.0% (95% 
confidence interval [95%CI]: 0.9%-1.1%), were from a 2013 Indonesian MoH report(6). The 
proportion of PWID among adults in Indonesia, 0.11% (95%CI: 0.09%-0.13%) and anti-HCV 
prevalence among PWID, 89.2% (95%CI: 85.8%-92.6%) were taken from a recent systematic review 
and data from PKNI(19, 20). The supplement gives further parameterization information. 
Selecting the most feasible scenario 
Stakeholders, including the MoH, were consulted to understand the limitations on program capacity 
for scale-up. The elimination 2045 scenario was selected as the most feasible option for Indonesia as 
stakeholders judged the other scenarios to demand too steep a scale-up. Given Indonesia was 
treating <1,000 patients annually in 2017, the other elimination scenarios would have required over 
a 100-fold increase in patients treated within five years. 
Five-year cost estimation 
To inform immediate-term government planning efforts, we estimated the costs of the first five 
years of an elimination effort under the 2045 scenario, using the aforementioned framework (table 
1). Where possible, a unit cost per activity was estimated based on literature review, interviews with 
key information holders, and a review of MoH and PKNI documents. Table 2 contains key costing 
assumptions, including a baseline unit cost of $1,314 for a 12-week course of DAAs(21). Full unit 
costs and sources are listed in the supplement. Unit costs were multiplied by scale factors, based on 
the coverage output of the epidemiological modelling when relevant, such as for treatment 
activities, or based on stakeholder consultations and review of plans from other countries(13, 14, 
17). Scale factors for the first five years are shown in the strategy framework in the supplement(22). 
Priority areas of prevention, lab capacity decentralization, monitoring and evaluation, and 
management and coordination could not be costed based on the limited information available. A 
25% mark-up of the costs of the other costed priority areas was used as a benchmark for the costs of 
these supporting activities, based on reviewing other national strategy costings. 
Costs are given in US dollars ($). Future costs were inflation-adjusted at a rate of 2.2%. 
Long-term costing estimation 
We approximated the long-term costs of elimination for 2018-2050, with details given in the 
supplement. These costs focused on screening, diagnosis, and treatment since these activities were 
readily scalable based on treatment coverage targets. Other supporting program activities 
(awareness, lab strengthening, surveillance, etc.) were costed using the same mark-up of 25% as the 





Additional analyses examined how the long-term costs would change over time if key price 
reductions were secured. The following price reductions were explored:  
• 1: DAA price per treatment course drops from $1,314 (baseline) for Sofosbuvir/Daclatasvir 
(SOF/DAC) to $600 immediately, a price already seen in 2017 in other lower- and middle-
income countries (LMICs)(23) 
• 2: DAA price per treatment course drops to $150 over first five years, the lowest price for 
generic SOF/DAC reported in 2017(23) 
• 3: Viral load (VL) test price drops from $139 to $40 over the first five years, the lower end for 
reported VL prices in the public sector where patient payments are required(24) 
• 4: A combination of price reductions 2 and 3 
 
Advanced liver disease treatment costs 
In addition to the projected costs of a DAA treatment program, the costs of treating advanced liver 
(CC, DC, and HCC) for treatment-naïve patients were estimated for each scenario. Epidemiological 
modelling outputs were used for annual CC and DC cases. The ratio of DC cases to cases of HCC of 
0.44 from previous modelling work(13) was used to estimate the number of additional HCC cases 
annually. It was assumed that at baseline 75% of individuals in each disease stage category received 
treatment annually. Other models have assumed 80% treatment coverage for advanced liver 
disease(14). The number of cases treated each year was multiplied by an average disease-stage-
specific annual cost of treatment. These costs were $403 for CC, $3,050 for DC, and $2,850 for HCC, 
based on data from local hospitals(25, 26). 
Cost-effectiveness analysis 
An incremental cost-effectiveness ratio (ICER) was calculated for the 2045 elimination scenario by 
examining long-term costs and benefits relative to the baseline scenario. The cost-effectiveness 
analysis was conducted from a societal perspective. Long-term costs included both direct DAA 
program costs and advanced liver disease treatment costs for DAA-naïve patients from 2018-2050 to 
capture the total costs of treating hepatitis complications with and without the availability of DAA 
treatment. Impact was measured in additional years of life saved (YLS), or years of life lost averted 
(YLL averted). The supplement contains details on how deaths averted were transformed to YLS. The 
ICER for the 2045 elimination scenario was evaluated for the four price reduction options. ICERs 
were compared to relevant benchmarks, including the gross domestic product (GDP) per capita and 
other Indonesia-specific disease programs(27).  
Sensitivity analyses 
Given the high uncertainty around key epidemiological parameters, we performed a wide range of 
sensitivity analyses. These included assuming: (a) 50% of infected individuals are treated annually 
when the numbers of infected individuals is lower than the number of annual treatments available; 
(b) a stable general population HCV prevalence (rather than decreasing); (c) a lower general 
population anti-HCV prevalence (0.8%)(11, 28, 29); (d) a lower PWID anti-HCV prevalence (50%); (e) 
a lower proportion of adults that are PWID (0.02%)(30); (f) a higher viraemic HCV proportion 
(0.76)(31); (g) a lower (-50%) and higher (+50%) rate of progression from chronic infection to 
cirrhosis. We investigated selecting PWID for the first 32,000 treatments (total treatments over 




cirrhosis for the first 32,000 treatments, and selecting those with decompensated cirrhosis for the 
first 32,000 treatments (patients with compensated and decompensated cirrhosis have higher 
mortality(34)). Additionally, given the lack of Indonesia-specific data on screening program yield to 
date, we examined a range of expected yields from general population screening (+50%, -50%). We 
also performed sensitivity analyses for higher (+25%) and lower (-25%) assumptions for access to 
care for advanced liver disease. 
Results 
Treatment coverage 
Figure 1 and supplementary table 1 show the coverage curves for the four scale-up scenarios. The 
2036 elimination scenario, the most aggressive option, peaks at 1 million annual treatments in 2020. 
The 2040 elimination scenario would treat over 200,000 persons annually by 2022, with a peak of 
550,000 annual treatments in 2025. The 2042 elimination is more conservative but still reaches over 
100,000 treatments in 2022, peaking at 370,000 treatments from 2027-2029. The 2045 scenario is 
the most conservative in the first five years, with only 40,000 treatments in 2022, and has the lowest 
overall peak of 250,000 treatments from 2028-2031. The 2045 scenario hits 100,000 annual 
treatments 3-5 years after the other scenarios, allowing more time for capacity building and 
resource mobilization.  
Disease impact 
Each scale-up scenario eventually achieves both the WHO elimination incidence and mortality 
targets. The 2036 elimination scenario would have the greatest impact on deaths and new infections 
averted due to treating more individuals earlier on and preventing progression to advanced disease. 
Each scenario achieves the incidence reduction targets around 13 years before the mortality 
reduction targets. 
With the no treatment scenario, prevalent infections are estimated to decrease slightly from 1.57 
million in 2015 to 1.43 million infections by 2050 due to a declining epidemic. Nonetheless, the 
estimated number of new infections is projected to remain fairly stable (between 34,000-37,000 
annual infections during 2015-2050), resulting in 1.29 million total new infections over the 35-year 
period. Elimination by 2036 would prevent around 900,000 of these new infections (70% of the no 
treatment scenario) while 2045 elimination would prevent about 739,000 infections (57%); figure 2a. 
Under the no treatment scenario HCV-related deaths increase from 9,000 annually in 2015 to 12,500 
in 2050; cumulatively over 429,000 deaths by 2050. The 2036 scenario would prevent around 
203,000 deaths from 2018-2050 (47% of the no treatment scenario), while the 2045 scenario would 
avert over 158,000 deaths (37%); figure 2b.  
Around 362,000 individuals are expected to develop CC and 90,000 DC by 2050 under the no 
treatment scenario. Elimination by 2036 would result in around 220,000 fewer individuals with CC 
and 78,000 fewer with DC in 2050. Elimination by 2045 is estimated to result in 173,000 fewer 
people with CC and 73,000 fewer with DC in 2050. Supplementary table 2 shows the number of CC 





The cost of a five-year program under the 2045 scenario is estimated at approximately $347 million. 
Table 3 shows the breakdown by priority area. Of the $347 million, DAA diagnosis and treatment 
represent 58% of the five-year costs ($202 million) and screening accounts for 17% ($59 million). The 
2018 Indonesian MoH budget is $7.0 billion and projected at $8.4 billion in 2019, so on average HCV 
scale-up could amount to less than 1% of the Indonesian health budget for the first five years(35). 
Under the 2045 scenario, the total costs of elimination were estimated at about $5.6 billion for 
2018-2050 (table 4). Around 44% of costs would be for treatment, 28% for screening, 8% for 
diagnostic evaluations, and 20% for other supporting activities. When conservatively assuming a 
constant MoH budget, HCV elimination would require, on average, 2.1% of the budget from 2018-
2050(32).  
If a price of $600 per treatment course is secured before scale-up begins (price reduction 1), total 
program costs for 2018-2050 would be reduced by 30% to $3.9 billion. If DAA prices in Indonesia can 
be reduced gradually to $150 over the next five years, the total costs of elimination could be 
lowered by 48% to $2.9 billion (price reduction 2). If VL test prices are reduced to $40 over the next 
five years, this would cut total program costs by 5% (price reduction 3). A combination of reduced 
DAA and VL costs over the next five years could reduce the total program cost by around 52%, to an 
estimated $2.7 billion (price reduction 4).  
Under the no treatment scenario, the total costs of treating advanced liver disease would be $8.1 
billion for 2018-2050. Under the 2045 elimination scenario, these treatment costs would be reduced 
to $6.4 billion; saving around $1.7 billion.  
Cost-effectiveness analysis 
The ICER of the 2045 scenario was $1,247 per YLS compared to the no treatment scenario, about 
one third of Indonesia’s GDP per capita ($3,847)(36). If the DAA price of $600 is secured (price 
reduction 1), the ICER per YLS would be $712 while at the even lower $150 per cure (price reduction 
2) the ICER would drop to $390 per YLS. If the cost of drugs and VL testing are lowered together as in 
price reduction 4, elimination would generate an ICER of $300 per YLS, less than a tenth of 
Indonesia’s GDP per capita. Even at baseline prices for DAAs and VL testing, the ICER for HCV 
elimination compares favourably to the ICERs associated with the proposed scale-up of other 
disease interventions in Indonesia(37-39). 
Sensitivity analyses  
The sensitivity analyses for the epidemiological modelling assumptions all produce similar ICERs to 
the baseline assumptions, except the assumptions regarding the progression rate from chronic 
infection to cirrhosis (table 5). For all assumptions ICERs were cost-effective. When, for the same 
treatment levels as the 2045 elimination scenario, we allocated the first three years of treatment to 
people with compensated cirrhosis, the number of HCV-related deaths in 2030 was slightly lower 
(10,021 vs 10,179). When these treatments were allocated to those with decompensated cirrhosis, 
there was a slightly higher number of HCV-related deaths in 2030 (10,310 vs 10,179). When 
allocating the first three years of treatments to PWID, there was a slightly lower number of incident 
infections in 2030 (20,228 vs 20,679). If assuming that 50% of remaining infections are treated, 




infections, elimination is reached only one year later (supplementary table 10). When it was 
assumed yield from general population screening was 50% less at 1.50%, the total costs of the 
program increased to $7.6 billion. At a yield of 4.5%, total program costs are estimated to be 
reduced to $4.9 billion. Supplementary figure 3 gives the estimated costs of elimination for the full 
range of 1.5-4.5% screening yield among high-risk groups in the general population. The sensitivity 
of the program’s cost-effectiveness to assumptions on access to advanced liver disease care are 
described in supplementary table 12.  
 
Discussion 
This study is the first to propose a framework for HCV elimination in Indonesia, a country with one of 
the world’s largest HCV burdens(40). The analysis provides evidence to support a decision to pursue 
HCV elimination in Indonesia and offers inputs that could help shape subsequent planning efforts. 
This program’s benefits in terms of deaths and infections averted and reductions in liver disease 
would be significant.   
We focus on an elimination scenario endorsed by local stakeholders accounting for the reality that 
time will be required to mobilize resources and build capacity for a large-scale elimination program. 
The program achieves elimination by 2045, while meeting the incidence reduction target by 2032. 
Over the first five years, this 2045 scenario would grow to treat 40,000 patients annually and is 
projected to cost $347 million, an average of around $69 million a year. This path to elimination 
would reach its peak intensity treating 250,000 patients annually from 2028-2031. In addition to 
eliminating HCV, over 184,000 deaths and 735,000 new HCV infections would be prevented between 
2018-2050 and there would be 247,000 fewer individuals living with liver cirrhosis in 2050.  
The total cost of elimination through 2050 was estimated at $5.7 billion, a significant amount of 
money for Indonesia, averaging around $180 million per year. These additional investments would 
likely be highly cost-effective, as the cost per YLS ($1,247) is less than Indonesia’s GDP per capita 
($3,847)(36). If price reductions for drugs and tests are achieved, HCV elimination would become 
even more cost-effective. The ICERs presented compare favourably to the ICERs associated with 
other proposed interventions in Indonesia such as an improved targeted screening policy for 
noncommunicable disease (~3,700 per disability adjusted life year [DALY] averted)(39), school-based 
delivery of the oral cholera vaccine (~$2,500 per DALY averted)(37), and improved sanitation 
interventions ($1,400-$2,700 per DALY averted)(38).  
Indonesia’s 2018 MoH budget was approximately $7.0 billion and was projected to increase to $8.4 
billion in 2019(35). We approximate that at these levels, the first five years of the national program 
would require less than 1% of Indonesia’ health budget and less than 2.5% on average over the 
course of elimination. Further analysis must be conducted on the short-term and long-term 
financing options for Indonesia, accounting for the MoH budget, current spending on hepatitis, fiscal 
space for the hepatitis elimination program, and potential for obtaining financing from external 
sources such as development banks.  
This analysis highlights the influence of specific policies on program costs, such as securing price 




population. This will be driven by prices negotiated by the MoH for DAAs and viral load tests, with 
potential cost savings of $3 billion. In the sensitivity analysis, we found that targeting treatment first 
to PWID or those with compensated cirrhosis could avert more new infections or deaths. Targeting 
treatment in the early years would require a screening strategy that enables the program to identify 
these specific populations. This approach for Indonesia could be even more important given the 
sensitivity of program costs to the screening strategy effectiveness (yield of testing). Inefficient 
screening approaches could jeopardize the overall program affordability in the Indonesian context. 
Higher screening yield can be achieved by developing targeted screening strategies and maintaining 
high linkage to care. In many countries, there is evidence that high screening yields can be attained 
in early HCV treatment programs when PWID are targeted since they often bear a disproportionate 
high burden of disease (41, 42). Individuals with compensated cirrhosis could be easier to link to 
treatment if already known to providers, but additional groups to target could include individuals 
who received blood transfusions before the introduction of HCV blood screening(43); populations 
with high-risk healthcare exposures (eg. re-use of medical injections); and prisoners(44). Further 
analysis of the HCV burden among these groups in Indonesia is warranted.  
Other literature 
To our knowledge, no other published study has investigated treatment costs of a national 
treatment program to eliminate HCV in Indonesia or has proposed a framework for designing a 
national hepatitis elimination program. A limited number of studies have estimated the 
epidemiological burden. Sibley et al estimated around 24,800 new cases of HCV in Indonesia 
occurred in 2014, Heffernan et al estimated 37,000, whilst we estimated around 34,000(28, 45). 
Sibley et al estimated around 20,000 people will have DC in 2030, whilst we estimated a much higher 
figure of 90,000(28). In 2030, Sibley et al estimated around 8,000 HCV-related deaths will occur, 
Heffernan et al estimated 13,000, and we estimated around 12,000(28, 45). The discrepancies 
between Sibley’s paper and those by ourselves and Heffernan are partly due to different methods 
used to estimate annual incidence (expert consensus vs dynamic modelling). Sibley et al used lower 
estimates of chronic prevalent infections in the general population and lower HCV prevalence 
among PWID(28), which we explored in sensitivity analyses. There were also disparities in model 
parameterisation regarding disease progression; we assumed an average of around 48 years to 
progress from chronic infection to cirrhosis, in line with other evidence(46), varying this parameter 
in sensitivity analyses to account for uncertainty. Several other studies have looked at the cost-
effectiveness of HCV elimination in different settings. Despite the differences in the model types 
used and the units of analysis, eg. YLS, disability adjusted life years saved, all the analyses identified 
found HCV elimination to be cost-effective (in Australia(47), South Africa(48), Morocco(14), and 
Greece(49)), whilst a study in Pakistan, found it cost saving(50). 
Strengths and limitations 
The strengths of this study’s epidemiological modelling include accounting for the HCV epidemic 
amongst PWID in Indonesia, vertical HCV transmission, age demographics, and population growth. 
One limitation was the lack of high-quality data. National estimates for the size of the PWID 
population, the HCV prevalence among the general population, and the HCV prevalence among 
PWID were important parameters with limited evidence. However, uncertainty extended to all 




Another challenge was the lack of a strategy and operational plan to inform the scenarios and 
costing. Due to this, we adopted a strategic plan framework based on examples from other 
countries(13, 14, 17). For some areas, eg. prevention and lab strengthening, costing data were 
unavailable, and we were forced to use broad coefficients from these other countries. Once a 
national elimination strategy for Indonesia is finalized, new cost estimations should be made using 
more precise unit costs and other assumptions, in consultation with stakeholders. 
Further work is required to understand best practices and effectiveness of mass screening strategies 
in LMIC settings(44). Most evidence exists for high-income countries, with few studies in LMICs. This 
analysis’s cost estimates could be improved by linking a dynamic screening model to our dynamic 
transmission model. 
Importantly, the interpretation of cost-effectiveness is partially driven by the assumption that in the 
absence of DAAs, patients with advanced liver disease would seek and receive treatment and thus 
there are cost offsets to be gained from averting healthcare costs. Due to the lack of Indonesia-
specific data, we assumed that 75% of patients with advanced liver disease would be treated. If 
these patients did not seek and receive treatment in Indonesia, these costs would not be incurred 
and would not be counted as savings. We accounted for this uncertainty in our sensitivity analysis, 
but additional data collection on access to care for patients with advanced liver disease are needed.  
Policy Relevance   
This paper shows how a combination of epidemiological and economic analyses can be used to 
produce evidence on the likely costs and benefits of HCV elimination over several decades. These 
analyses help to define what actions must be taken, the resources required, and the expected public 
health impacts that can be achieved. In Indonesia, PKNI has presented our findings to the Committee 
of the Indonesian Legislature Body, the committee for health affairs, and directly to the Minister of 
Health. Looking forward, this study could help the government to develop a national strategic plan 
that could prevent 739,000 new infections and 158,000 deaths and put Indonesia on the road to 
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Table 1: Proposed strategic framework for five-year national plan  












1. Awareness Raising 
A. Conduct a national awareness campaign 
B. Participate in World Hepatitis Day Activities 
C. Conduct community workshops in high burden areas 
2. Healthcare Training 
A. Disseminate guidelines to healthcare workers 
B. Conduct treatment educator training 
C. Train medical and paramedical personnel involved in screening for HCV 
3. Prevention Activities  
A. Support harm reduction activities 
B. Promote bloody safety  
C. Promote injection safety in healthcare settings 
4. Strategic Information 
A. Conduct a national serosurvey study 
B. Conduct special survey of high–risk populations 
5. Lab strengthening 
A. Decentralize viral load testing 
B. Decentralize diagnostic capabilities for liver fibrosis screening 
Core program 
6. Screening  
A. Implement routine screening in high-risk populations (PWID, MSM) 
B. Implement general population screening 
7. Treatment 
A. Improve access to diagnostics 
B. Improve access to DAA therapy 
8. M&E Improve surveillance to support routine data collection 
9. Management & Coordination Oversee program implementation and improve efficiencies when possible 
 †HCV: Hepatitis C virus; PWID: People who inject drugs; MSM: Men who have sex with men 
Table 2: Key costing assumptions for baseline scenarios 
Key price assumptions Cost (USD) Cost (IDR M) Source 
Hepatitis C virus rapid diagnostic test (RDT) 10 0.1 Ministry of Health 
Viral load test (VL) 139 1.9 St Carolus Hospital 
Fibroscan 74 1.0 PPHI (Liver Association of Indonesia) 
Direct acting antivirals (DAAs), per 12-week 
course 
1,314 18.0 PKNI 
Average cost per activity 
(including all cost inputs, i.e. service delivery, 
drugs, etc) 
Cost (USD) Cost (IDR M) Source 
Average cost per person screened 17 0.2 Ministry of Health, St Carolus Hospital 
Average cost per person diagnosed 191 2.6 PPHI, St Carolus Hospital 
Average cost per person treated 1,437 19.8 PKNI 




Table 3: Costs in US dollars (USD) of a five-year hepatitis program under the 2045 elimination 
scenario  
Priority area Year 1 Year 2 Year 3 Year 4 Year 5 Total costs 
Awareness raising 0.2 M 0.2 M 0.2 M 0.2 M 0.2 M 1.0 M (<1%) 
Healthcare training 0.5 M 4.6 M 0.8 M 4.8 M 0.7 M 11.4 M (3%) 
Prevention† † † † † † † 
Strategic information 0.03 M 1.9 M 0.03 M - 2.1 M 4.1 M (1%) 
Lab strengthening† † † † † † † 
Screening 5.1 M 8.0 M 13.4 M 13.7 M 19.4 M 59.5 M (17%) 
Diagnosis + Treatment 15.6 M 22.4 M 32.9 M 44.2 M 86.7 M 201.8 M (58%) 
Monitoring & evaluation† † † † † † † 
Total 21.4 M 37.1 M 47.3 M 62.8 M 109.2 M 277.7 M 
Total + 25% 26.7 M 46.4 M 59.1 M 78.6 M 136.4 M 347.1 M 
†These activities were not costed because they are not readily scaled based on treatment coverage 
estimates. We applied a 25% mark-up to the total costs of the costed activities to account for these 
priority areas.  
 
Table 4: Total costs of treating liver disease over time with different pricing assumptions, 2018-2050, 
in US dollars (USD) 
 Status quo Elimination 2045 












Assumptions       
DAA price - 1314  600  150 by Y5 1314 150 by Y5 
Viral load test price - 139 1340 139  40  40  
Costs       
DAA program costs - 5.6 B  3.9 B 2.9 B 5.3 B 2.7 B 
Advanced liver disease treatment 
costs 
8.1 B 6.4 B 6.4 B 6.4 B 6.4 B 6.4 B 
DAA program + Advanced liver 
disease treatment costs 
8.1 B 12.0 B 10.3 B 9.3 B 11.7 B 9.0 B 
Cost-effectiveness analysis       
Total incremental costs vs no 
treatment scenario 
- 3.9 B 2.2 B 1.2 B 3.6 B 0.9 B 
Incremental YLS vs no treatment 
scenario 
- 3.1 M 3.1 M 3.1 M 3.1 M 3.1 M 
Cost-effectiveness ratio (USD per 
death averted compared to SQ) 
- 1,247 712 390 1,157 300  





Table 5: Sensitivity analyses testing various assumptions around the epidemiological inputs of the model, with outputs values given for 2015, and ICERs* 













Baseline ICER*  Price reduction 
scenario 4 ICER* 
Baseline scenario 1,570,342 326,901 64,959 34,392 9,050 1,247 300 
Assuming a stable, rather than 
decreasing epidemic 
1,593,055 312,671 60,767 45,844 8,477 941 44 
Assuming a lower general 
population HCV prevalence 
(0.8%)(29) 
1,268,104 261,099 51,750 29,506 7,210 1,153 265 
Assuming a lower PWID anti-
HCV prevalence (50%) 
1,564,577 330,648 65,871 31,160 9,206 1,132 255 
Assuming a lower proportion of 
adults that inject drugs 
(0.02%)(30) 
1,559,156 334,596 67,045 26,663 9,363 1,192 264 
Assuming a higher viraemic 
proportion (0.76)(31) 
1,872,029 390,359 77,555 40,384 10,755 1,267 326 
Assuming a 50% lower 
progression rate from chronic 
infection to cirrhosis (0.0105) 
1,575,985 177,262 34,836 32,689 4,864 2,370 902 
Assuming a 50% higher 
progression rate from chronic 
infection to cirrhosis (0.0315) 
1,565,838 451,556 91,390 35,937 12,705 859 107 




Figure 1: Treatment coverage of the elimination scale-up scenarios, 2018-2050. 
 
Figure 2: Number of new chronic HCV infections (panel a) and HCV-related deaths (panel b) annually 
for the elimination scale-up scenarios and the status quo, 2018-2050. Dashed lines are WHO 
reduction targets. 
 
 
